AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CVKD
  4. [8-K] Cadrenal Therapeutics, Inc. Reports Material Event

[8-K] Cadrenal Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock CVKD logo
Cadrenal Therape

NASDAQ:CVKD

CVKD Rankings

#8979 Ranked by Market Cap
N/A Ranked by Dividends

CVKD Latest News

Aug 5, 2025
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
Jun 12, 2025
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
Jun 4, 2025
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
May 15, 2025
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
May 8, 2025
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

CVKD Latest SEC Filings

Aug 5, 2025
[8-K] Cadrenal Therapeutics, Inc. Reports Material Event
Jul 31, 2025
[DEF 14A] Cadrenal Therapeutics, Inc. Definitive Proxy Statement

CVKD Stock Data

20.32M
1.39M
28.19%
7.38%
1.03%
Biotechnology
Pharmaceutical Preparations
United States
PONTE VEDRA